|
|
|
February 17, 2012 | The biotech investment model is changing. Venture capitalists are no longer willing to wait for a return on their investment while science does its thing. There is a trend toward very small, single-project companies that are more compelling to big company buyers. But what does this change investment strategy mean for the actual research and drug discovery? Xconomy
|
|
|